De Luca Rossella, Blasi Livio, Alù Massimiliano, Gristina Valerio, Cicero Giuseppe
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
Medical Oncology Unit, ARNAS Hospital Civico, Di Cristina, Benfratelli, Palermo, Italy.
Drug Des Devel Ther. 2018 Jun 19;12:1769-1775. doi: 10.2147/DDDT.S165851. eCollection 2018.
Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC).
We conducted a retrospective analysis of 80 patients. Overall survival (OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, progression-free survival (PFS), overall response rate and reduction in pain were secondary end points.
The median OS was 8 months, and the median PFS was 5 months. A considerable difference in CA 19-9 before and after treatment was observed. Descriptive and correlation analyses were done to examine the relationship between CA 19-9 response and OS. Linear regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important predictor of OS, showing a positive correlation.
Nab-paclitaxel is a well-tolerated and effective treatment for patients affected by MPC. The drug showed an improved tolerability profile, significant pain relief and an increase in survival rate.
胰腺癌是死亡率极高的肿瘤，该癌症的主要标准治疗方法虽能提高生存率，但无法使患者完全康复。本研究旨在评估艾日布林（纳米白蛋白结合型紫杉醇）对意大利转移性胰腺癌（MPC）患者的疗效。
我们对80例患者进行了回顾性分析。总生存期（OS）是评估纳米白蛋白结合型紫杉醇联合吉西他滨治疗疗效的主要终点，而糖类抗原19-9（CA 19-9）降低、安全性、无进展生存期（PFS）、总缓解率和疼痛减轻则是次要终点。
中位总生存期为8个月，中位无进展生存期为5个月。观察到治疗前后CA 19-9有显著差异。进行了描述性和相关性分析以检验CA 19-9反应与总生存期之间的关系。总生存期与CA 19-9反应之间的线性回归分析显示，CA 19-9是总生存期的重要预测指标，呈正相关。
纳米白蛋白结合型紫杉醇对MPC患者是一种耐受性良好且有效的治疗方法。该药物显示出更好的耐受性、显著的疼痛缓解和生存率提高。
